Back

Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Triple therapy in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Vagner Madrini

Albert Einstein Israelite Hospital, Sao Paulo (Brazil)

6 More presentations in this session

Presentation thumbnail
Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial
Doctor P. Guimaraes (Sao Paulo, BR)
Abstract
Presentation thumbnail
Initial triple low-dose combination therapy improves blood pressure control without increased adverse events: a systematic review and meta-analysis
Associate Professor J. Park (Goyang, KR)
Abstract
Presentation thumbnail
Treatment escalation beyond triple therapy in patients with resistant hypertension: a population-based observational cohort study from UK healthcare records
Doctor P. Swift (London, GB)
Abstract
Presentation thumbnail
Efficacy and safety of intensive versus standard systolic blood pressure treatment: A systematic review and meta-analysis
Associate Professor O. Rueda Ochoa (Bucaramanga, CO)
Abstract
Presentation thumbnail
Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial
Doctor V. Madrini (Sao Paulo, BR)
Abstract

Access the full session

Session thumbnail
Triple therapy in hypertension

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of blood pressure reduction on cardiovascular outcomes in patients with different baseline cardiovascular risk: systematic review and meta-analysis of randomized trials
28 August 2022
thumbnail
Congress Presentation
Novel Triple Single-Pill for Uncontrolled Hypertension
29 August 2025
thumbnail
Congress Presentation
Successful perindopril/amlodipine+indapamide treatment as second line in uncontrolled hypertensive patients in line with european guidelines
7 April 2022
thumbnail
Congress Presentation
An observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources